Subscribe
jeffhochstrasser-istockphoto
jeffhochstrasser / iStockphoto.com
28 June 2017Americas

Federal Circuit vacates PTAB’s decision on foetal testing patent

The US Court of Appeals for the Federal Circuit has vacated and remanded the Patent Trial and Appeal Board’s (PTAB) decision to invalidate a foetal testing patent.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Fed Circuit rejects Stanford DNA test appeal
11 July 2019   The US Court of Appeals for the Federal Circuit yesterday, July 10, handed victory to researchers at the Chinese University of Hong Kong in a case involving a foetal testing patent.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Americas
Fed Circuit rejects Stanford DNA test appeal
11 July 2019   The US Court of Appeals for the Federal Circuit yesterday, July 10, handed victory to researchers at the Chinese University of Hong Kong in a case involving a foetal testing patent.

More on this story

Americas
Fed Circuit rejects Stanford DNA test appeal
11 July 2019   The US Court of Appeals for the Federal Circuit yesterday, July 10, handed victory to researchers at the Chinese University of Hong Kong in a case involving a foetal testing patent.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York